EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Innovative all‐in‐one exome sequencing strategy for diagnostic genetic testing in male infertility: Validation and 10‐month experience

Manon S Oud iD, Nicole de Leeuw, Dominique F C M Smeets, Liliana Ramos iD, Godfried W van der Heijden, Raoul G J Timmermans, Maartje van de Vorst, Tom Hofste, Marlies J E Kempers, Marijn F Stokman, Kathleen W M D'Hauwers, Brigitte H W Faas und 1 weitere

Andrology · 2025

DOI: 10.1111/andr.13742 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Andrology, 2025. Verfasst von Manon S Oud und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Infertility, Male, Genetic Testing, Exome Sequencing, Azoospermia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines indicate that patients with extreme oligozoospermia or azoospermia should be tested for chromosomal imbalances, azoospermia factor (AZF) deletions and/or CFTR variants. For other sperm abnormalities, no genetic diagnostics are recommended.

Objectives

To determine whether exome sequencing (ES) with combined copy number variant (CNV) and single nucleotide variant (SNV) analysis is a reliable first‐tier method to replace current methods (validation study), and to evaluate the diagnostic yield after 10 months of implementation (evaluation study). Materials and Methods In the validation study, ES was performed on DNA of patients already diagnosed with AZF deletions ( n = 17), (non‐)mosaic sex chromosomal aneuploidies or structural chromosomal anomalies ( n = 37), CFTR variants ( n = 26), or variants in known infertility genes ( n = 4), and 90 controls. The data were analyzed using our standard diagnostic pipeline, with a bioinformatic filter for 130 male infertility genes. In the evaluation study, results of 292 clinical exomes were included.

Results

All previously reported variants in the validation cohort, including clinically relevant Y‐chromosomal microdeletions, were correctly identified and reliably detected. In the evaluation study, we identified one or more clinically relevant genetic anomalies in 67 of 292 of all cases (22.9%): these included aberrations that could have been detected with current methods in 30 of 67 patients (10.2% of total), (possible) (mono)genetic causes in the male infertility gene panel in 28 of 67 patients (9.6%), and carriership of cystic fibrosis in nine of 67 patients (3.1%).

Conclusion

ES is a reliable first‐tier method to detect the most common genetic causes of male infertility and, as additional genetic causes can be detected, in our evaluation cohort the diagnostic yield almost doubled (10.2%–19.8%, excluding CF carriers). A genetic diagnosis provides answers on the cause of infertility and helps the professionals in the counseling for treatment, possible co‐morbidities and risk for offspring and/or family members. Karyotyping will still remain necessary for detecting balanced translocations or low‐grade chromosomal mosaicism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infertility, MaleGenetic TestingExome SequencingAzoospermiaOligospermiaHumansMaleDNA Copy Number VariationsAdultCystic Fibrosis Transmembrane Conductance RegulatorPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

asthenozoospermiaazoospermiadiagnosticsgene panelgenetic testinggeneticsmale infertilityoligozoospermiateratozoospermia

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.
  • Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, The Netherlands.
  • Department of Urology, Radboud university medical center, Nijmegen, The Netherlands.

ORCID-Profile: Manon S Oud, Liliana Ramos, Dineke Westra

Zitieren

APA

Oud, M. S., de Leeuw, N., Smeets, D. F. C. M., Ramos, L., van der Heijden, G. W., Timmermans, R. G. J., van de Vorst, M., Hofste, T., Kempers, M. J. E., Stokman, M. F., D'Hauwers, K. W. M., Faas, B. H. W., & Westra, D. (2025). Innovative all‐in‐one exome sequencing strategy for diagnostic genetic testing in male infertility: Validation and 10‐month experience. Andrology. https://doi.org/10.1111/andr.13742

Vancouver

Oud MS, de Leeuw N, Smeets DFCM, Ramos L, van der Heijden GW, Timmermans RGJ, et al. Innovative all‐in‐one exome sequencing strategy for diagnostic genetic testing in male infertility: Validation and 10‐month experience. Andrology. 2025. doi:10.1111/andr.13742

BibTeX
@article{Oud2025,
  author = {Oud, Manon S and de Leeuw, Nicole and Smeets, Dominique F C M and Ramos, Liliana and van der Heijden, Godfried W and Timmermans, Raoul G J and van de Vorst, Maartje and Hofste, Tom and Kempers, Marlies J E and Stokman, Marijn F and D'Hauwers, Kathleen W M and Faas, Brigitte H W and Westra, Dineke},
  title = {Innovative all‐in‐one exome sequencing strategy for diagnostic genetic testing in male infertility: Validation and 10‐month experience},
  journal = {Andrology},
  year = {2025},
  doi = {10.1111/andr.13742}
}
Kostenlos starten →